- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05882448
Untersuchung des Einflusses der intraperitonealen CO2-Insufflation mittels Laparoskopie auf die kurzfristige Entwicklung von Frühgeborenen mit ulzerativer nekrotisierender Enterokolitis (NECO2)
Untersuchung des Einflusses der intraperitonealen Insufflation von Kohlendioxid (CO2) durch Laparoskopie auf die kurzfristige Entwicklung von Frühgeborenen mit ulzerativer nekrotisierender Enterokolitis
Ulcerative-necrotizing enterocolitis (ECUN) is an infectious and inflammatory disease of the digestive tract, which can lead to intestinal necrosis or perforation.
This severe pathology of the newborn , often premature, requires urgent medical and surgical treatment in 25 to 50% of cases. The morbidity is high, both digestive and neurological. ECUN can lead to complications at short-term (death, intestinal stenosis) and at long-term (neuro-cognitive disorders). The challenge of preserving the neurological development is a major issue. It involves control of inflammation. This inflammation causes neurological lesions and is responsible for a disorder of the long-term neurocognitive development.
At Robert-Debré and Trousseau, the management of newborns with ECUN is focused on the control of this inflammation. A laparoscopy is performed first. The carbon dioxide (CO2) insufflated into the abdomen during a laparoscopy is thought to have an anti-inflammatory effect according to several experimental and clinical studies. A preliminary retrospective study at Robert-Debré showed a decrease in postoperative inflammation (decrease in C reactive protein at Day2 and Day 7 post-op) as well as a decrease in morbimortality (decrease in the rate of stoma and reoperation) in children who had a laparoscopic first operation compared to those who had a laparotomy alone. However, in many hospitals, laparotomy alone is currently the only surgical option.
This preliminary study may demonstrate that laparoscopy decreases early morbidity and mortality in children with ECUN through reduced inflammation, as reflected by postoperative C reactive protein.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
NECO2 is a pilot trial, evaluating the intermediate effectiveness to short/medium term of laparoscopy on the inflammatory reaction of premature newborns with complicated ECUN, requiring surgical treatment.
This is a multicenter randomized controlled trial in single blind, in two parallel arms, in ratio 1:1, of superiority.
This trial compares laparoscopy plus laparotomy versus laparotomy alone.
Children will be randomized into 2 groups:
- Laparoscopy + laparotomy group
- Laparotomy group
The main objective is to evaluate the inflammatory response Day 2 postoperative in preterm infants with ECUN who have undergone surgery.
The main criterion is the evolution of the blood C reactive protein level between Day 0 and Day 2 postoperatively.
The secondary objectives are:To evaluate in premature babies with ECUN who have had a surgical intervention (laparoscopy + laparotomy or laparotomy alone):
A.The postoperative biological inflammatory response at Day 7 B.Post-operative biological inflammatory response from Day 0 to Day 7 C.Post-operative mortality D.Post-operative bowel morbidity E.Post-operative re-intervention rate F.Length of hospital stay G.Post-operative neurological morbidity, medium term (corrected term 41 SA)
- To evaluate the tolerance of laparoscopy :
H.Intraoperative cardiorespiratory I.Loco-regional lesions linked to the insertion of the trocar
Secondary endpoints:
A. C reactive protein blood level at Day 7 B. Blood levels of Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha at Day 1, Day 2, Day 4, Day 7 C. Postoperative death from any cause D. Stoma rate, duration of parenteral nutrition, duration of hemodynamic support, duration of invasive ventilation (High frequency oscillatory ventilation/Synchronized Intermittent Mandatory Ventilation), Post-ECUN intestinal stenosis rate E. Re-intervention (laparotomy) and cause (post-ECUN stenosis, stoma closure) F. Length of hospital stay until return home G. Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at the corrected term of 41 weeks of amenorrhea, H. Oxygen saturation (SaO2), hypercapnia (pCO2) blood pressure (BP), cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively I. Intraoperative clinical monitoring: exploration of adjacent organs. Post-operative clinical monitoring: digestive signs monitoring of wounds until discharge.
Group 1: laparotomy only Group 2: laparotomy and laparoscopy
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Louise MONTALVA, Dr
- Telefonnummer: +33 1.71.73.89.97
- E-Mail: louise.montalva@aphp.fr
Studieren Sie die Kontaktsicherung
- Name: Arnaud BONNARD, Pr
- Telefonnummer: +33 1 40 03 23 59
- E-Mail: arnaud.bonnard@aphp.fr
Studienorte
-
-
-
Paris, Frankreich, 75012
- Rekrutierung
- Hôpital Armand Trousseau Service de Chirurgie Pédiatrique et Néonatale
-
Kontakt:
- MONTALVA Louise, Dr
- Telefonnummer: +33 +33 1.71.73.89.97
- E-Mail: louise.montalva@aphp.fr
-
Paris, Frankreich
- Rekrutierung
- Hôpital Robert Debré Service de Chirurgie Pédiatrique
-
Kontakt:
- BONNARD Arnaud, Pr
- Telefonnummer: +33 33 1 40 03 41 21
- E-Mail: arnaud.bonnard@aphp.fr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Premature newborn (term of birth: <37 weeks of amenorrhea)
- Diagnosis of ECUN by the surgeon (distension abdominal +/- rectal bleeding +/- green gastric residue, increased biological inflammatory syndrome, + pneumatosis on abdominal radiography)
- Hospitalized and complicated ECUN: presenting either a pneumoperitoneum on abdominal X-ray or a absence of clinical and biological improvement after 48 hours of maximum well-conducted medical treatment (IV antibiotic therapy and digestive rest).
- Hospitalized in the 2 participating centers
- Of which the 2 holders of parental authority have been informed and have signed the consent form
- Having social security coverage (social security or CMU)
Exclusion Criteria:
- Instability contraindicating movement to the operating room or contraindicating CO2 insufflation
- Diagnosis of isolated perforation of the small intestine (radiography:
pneumoperitoneum without pneumatosis)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Laparotomy
Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion |
Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion |
|
Experimental: Laparotomy and laparoscopy
Exploratory and therapeutic laparotomy if necessary preceded by laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes. |
Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
C reactive protein blood level
Zeitfenster: between Day 0 and Day 2 post surgery
|
C reactive protein blood level |
between Day 0 and Day 2 post surgery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative biological inflammatory reaction
Zeitfenster: Day 7 post surgery
|
C reactive protein blood level |
Day 7 post surgery
|
|
Specific post-operative biological inflammatory reaction
Zeitfenster: Day1, day 2, day 4 and day 7 post surgery
|
Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha blood level |
Day1, day 2, day 4 and day 7 post surgery
|
|
Postoperative mortality
Zeitfenster: up to 3 months
|
Death due to any postoperative cause |
up to 3 months
|
|
Postoperative intestinal morbidity: stoma rate
Zeitfenster: up to 3 months
|
Stoma rate |
up to 3 months
|
|
Postoperative intestinal morbidity: Duration of parenteral nutrition
Zeitfenster: up to 3 months
|
Duration of parenteral nutrition |
up to 3 months
|
|
Postoperative intestinal morbidity: Duration of hemodynamic support
Zeitfenster: up to 3 months
|
Duration of hemodynamic support |
up to 3 months
|
|
Postoperative intestinal morbidity: Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)
Zeitfenster: up to 3 months
|
Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation) |
up to 3 months
|
|
Postoperative intestinal morbidity: Rate of intestinal stenosis post-ECUN
Zeitfenster: up to 3 months
|
Rate of intestinal stenosis post-ECUN |
up to 3 months
|
|
Postoperative reoperation rate
Zeitfenster: up to 3 months
|
Reoperation (laparotomy) and cause (post ECUN stenosis, stoma closure) |
up to 3 months
|
|
Length of hospitalization
Zeitfenster: up to 3 months
|
Duration of hospitalization until return home |
up to 3 months
|
|
Medium-term postoperative neurological morbidity
Zeitfenster: up to 3 months
|
Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at term corrected for 41 weeks of amenorrhea |
up to 3 months
|
|
Oxygen saturation (SaO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Zeitfenster: During Surgery
|
Oxygen saturation (SaO2) |
During Surgery
|
|
Hypercapnia (pCO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Zeitfenster: During Surgery
|
hypercapnia (pCO2) |
During Surgery
|
|
Blood pressure (BP) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Zeitfenster: During Surgery
|
blood pressure (systolic and diastolic) |
During Surgery
|
|
Cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Zeitfenster: During Surgery
|
cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively |
During Surgery
|
|
Presence of loco-regional lesions related to the insertion of the trocar (Tolerance of laparoscopy)
Zeitfenster: up to 3 months
|
Presence of loco-regional lesions related to the insertion of the trocar |
up to 3 months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Darmerkrankungen
- Geburtshilfe, Frühgeburt
- Geburtsbedingte Geburtskomplikationen
- Schwangerschaftskomplikationen
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Gastroenteritis
- Enterokolitis
- Frühgeburt
- Enterokolitis, nekrotisierend
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Minimal invasive chirurgische Verfahren
- Diagnosetechniken, chirurgisch
- Endoskopie
- Laparoskopie
- Laparotomie
Andere Studien-ID-Nummern
- APHP221170
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .